124 related articles for article (PubMed ID: 11750578)
21. Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1.
Yacyshyn BR; Schievella A; Sewell KL; Tami JA
Clin Exp Immunol; 2005 Jul; 141(1):141-7. PubMed ID: 15958080
[TBL] [Abstract][Full Text] [Related]
22. ISIS 2302. Oligo-TCS.
Drugs R D; 1999 Mar; 1(3):265-7. PubMed ID: 10566042
[No Abstract] [Full Text] [Related]
23. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
Yacyshyn BR; Chey WY; Goff J; Salzberg B; Baerg R; Buchman AL; Tami J; Yu R; Gibiansky E; Shanahan WR;
Gut; 2002 Jul; 51(1):30-6. PubMed ID: 12077088
[TBL] [Abstract][Full Text] [Related]
24. Genetic therapy for transplant vascular sclerosis.
Bennett CF; Stepkowski SM
Transpl Immunol; 1997 Dec; 5(4):299-302. PubMed ID: 9504151
[No Abstract] [Full Text] [Related]
25. Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice.
Henry SP; Denny KH; Templin MV; Yu RZ; Levin AA
Birth Defects Res B Dev Reprod Toxicol; 2004 Dec; 71(6):359-67. PubMed ID: 15617021
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of intercellular adhesion molecule-1 protein expression by antisense oligonucleotides is neuroprotective after transient middle cerebral artery occlusion in rat.
Vemuganti R; Dempsey RJ; Bowen KK
Stroke; 2004 Jan; 35(1):179-84. PubMed ID: 14657453
[TBL] [Abstract][Full Text] [Related]
27. Technology evaluation: alicaforsen (Isis).
Gewirtz AT; Sitaraman SV
Curr Opin Mol Ther; 2005 Jun; 7(3):273-81. PubMed ID: 15977426
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of intercellular adhesion molecule-1 with antisense deoxynucleotides prolongs renal isograft survival in the rat.
Dragun D; Lukitsch I; Tullius SG; Qun Y; Park JK; Schneider W; Luft FC; Haller H
Kidney Int; 1998 Dec; 54(6):2113-22. PubMed ID: 9853277
[TBL] [Abstract][Full Text] [Related]
29. Antisense ICAM-1 oligonucleotides block allograft rejection in rats.
Stepkowski SM; Wang ME; Amante A; Kalinin D; Qu X; Blasdel T; Condon T; Kahan BD; Bennett FC
Transplant Proc; 1997; 29(1-2):1285. PubMed ID: 9123308
[No Abstract] [Full Text] [Related]
30. Midkine antisense oligodeoxyribonucleotide inhibits renal damage induced by ischemic reperfusion.
Sato W; Takei Y; Yuzawa Y; Matsuo S; Kadomatsu K; Muramatsu T
Kidney Int; 2005 Apr; 67(4):1330-9. PubMed ID: 15780085
[TBL] [Abstract][Full Text] [Related]
31. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease.
Schreiber S; Nikolaus S; Malchow H; Kruis W; Lochs H; Raedler A; Hahn EG; Krummenerl T; Steinmann G;
Gastroenterology; 2001 May; 120(6):1339-46. PubMed ID: 11313303
[TBL] [Abstract][Full Text] [Related]
32. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.
Yacyshyn BR; Bowen-Yacyshyn MB; Jewell L; Tami JA; Bennett CF; Kisner DL; Shanahan WR
Gastroenterology; 1998 Jun; 114(6):1133-42. PubMed ID: 9609749
[TBL] [Abstract][Full Text] [Related]
33. Optimization of ex vivo pressure mediated delivery of antisense oligodeoxynucleotides to ICAM-1 reduces reperfusion injury in rat cardiac allografts.
Feeley BT; Poston RS; Park AK; Ennen MP; Hoyt EG; Vriens PW; Robbins RC
Transplantation; 2000 Mar; 69(6):1067-74. PubMed ID: 10762209
[TBL] [Abstract][Full Text] [Related]
34. Tissue factor antisense oligonucleotides prevent renal ischemia-reperfusion injury.
Matsuyama M; Yoshimura R; Akioka K; Okamoto M; Ushigome H; Kadotani Y; Nakatani T; Yoshimura N
Transplantation; 2003 Sep; 76(5):786-91. PubMed ID: 14501854
[TBL] [Abstract][Full Text] [Related]
35. ICAM-1 and VCAM-1 antisense oligonucleotides attenuate in vivo leucocyte adherence and inflammation in rat inflammatory bowel disease.
Rijcken E; Krieglstein CF; Anthoni C; Laukoetter MG; Mennigen R; Spiegel HU; Senninger N; Bennett CF; Schuermann G
Gut; 2002 Oct; 51(4):529-35. PubMed ID: 12235075
[TBL] [Abstract][Full Text] [Related]
36. Antibodies to ICAM-1 protect kidneys in severe ischemic reperfusion injury.
Rabb H; Mendiola CC; Saba SR; Dietz JR; Smith CW; Bonventre JV; Ramirez G
Biochem Biophys Res Commun; 1995 Jun; 211(1):67-73. PubMed ID: 7779111
[TBL] [Abstract][Full Text] [Related]
37. Tumor necrosis factor-a antisense transfer remarkably improves hepatic graft viability.
Yoshizumi T; Yonemitsu Y; Ikeda Y; Kaneda Y; Yanaga K; Sugimachi K; Sueishi K
Liver Int; 2006 May; 26(4):451-6. PubMed ID: 16629649
[TBL] [Abstract][Full Text] [Related]
38. [Antisense oligonucleotide attenuates renal tubulointerstitial injury in mice with unilateral ureteral obstruction].
Cheng Q; Chen X; Ye Y
Zhonghua Yi Xue Za Zhi; 1999 Jul; 79(7):533-7. PubMed ID: 11715426
[TBL] [Abstract][Full Text] [Related]
39. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302).
Watanabe TA; Geary RS; Levin AA
Oligonucleotides; 2006; 16(2):169-80. PubMed ID: 16764540
[TBL] [Abstract][Full Text] [Related]
40. Antisense oligodeoxynucleotides prevent acute cardiac allograft rejection via a novel, nontoxic, highly efficient transfection method.
Poston RS; Mann MJ; Hoyt EG; Ennen M; Dzau VJ; Robbins RC
Transplantation; 1999 Sep; 68(6):825-32. PubMed ID: 10515383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
